Calliditas Therapeutics AB (publ) (CALT)
| Market Cap | 590.39M |
| Revenue (ttm) | 119.73M |
| Net Income (ttm) | -46.25M |
| Shares Out | 26.84M |
| EPS (ttm) | -1.62 |
| PE Ratio | n/a |
| Forward PE | 18.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,284 |
| Open | 22.04 |
| Previous Close | 21.66 |
| Day's Range | 22.00 - 22.59 |
| 52-Week Range | 15.25 - 29.30 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 39.33 (+74.8%) |
| Earnings Date | May 28, 2024 |
About CALT
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical tr... [Read more]
Financial Performance
In 2023, CALT's revenue was 1.21 billion, an increase of 50.32% compared to the previous year's 802.88 million. Losses were -466.19 million, 13.1% more than in 2022.
Financial numbers in SEK Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CALT stock is "Strong Buy." The 12-month stock price forecast is $39.33, which is an increase of 74.80% from the latest price.
News
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
STOCKHOLM , May 16, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual R&D day on Thursd...
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
STOCKHOLM , May 15, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM: CALTX) ("Calliditas"), today announced upcoming data presentations and a sponsored symposium at th...
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
STOCKHOLM , May 15, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to t...
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
STOCKHOLM , May 14, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announces that its partner Everest Medicines (HKEX: 1952.HK) ("Everest...
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
STOCKHOLM , May 6, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setan...
Calliditas Therapeutics' 2023 Annual Report Published
STOCKHOLM , April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available at the ...
Calliditas Announces Positive NefIgArd Open Label Extension Results
STOCKHOLM , April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open-label extension (OLE) study to the P...
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
STOCKHOLM , April 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd...
Calliditas Therapeutics to Attend Conferences in April
STOCKHOLM , April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced tha...
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
STOCKHOLM , April 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations, as well as a sponsored sympos...
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
STOCKHOLM , April 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has received a Notice of Allowance from th...
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
SHANGHAI , March 11, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Callidi...
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
STOCKHOLM , March 6, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has granted an orphan drug exclusivity period...
Calliditas Therapeutics to Attend Investor Conferences in March
STOCKHOLM , March 1, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announce...
Calliditas Year-end report, January - December 2023
STOCKHOLM , Feb. 21, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX) 2023: Full approval for TARPEYO in the US; a year of successes OCTOBER – DECEMBER 2023(COMPARED TO OCTOBE...
Invitation to the presentation of Calliditas´ Year-end report January - December 2023
STOCKHOLM , Feb. 14, 2024 /PRNewswire/ -- Calliditas' Year-end report for January - December 2023 will be published in Swedish and English on Wednesday 21 February 2024 at 07.00 a.m. CET. A combined a...
Calliditas provides patent update
STOCKHOLM , Feb. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) i...
Calliditas Therapeutics provides business update ahead of JP Morgan conference
STOCKHOLM , Jan. 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today provided a business update...
Calliditas Therapeutics appoints Maria Törnsén as President North America
STOCKHOLM , Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced tha...
Calliditas to present at JP Morgan Healthcare Conference
STOCKHOLM , Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the 42nd ...
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital
STOCKHOLM , Dec. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed and fully drawn a term loan...
Calliditas Therapeutics stock jumps as kidney treatment gets FDA approval
Calliditas Therapeutics AB's American depositary receipts CALT, +6.84% jumped 15% premarket on Thursday after the company said late Wednesday that its kidney treatment Tarpeyo received full approval f...
US FDA approves Sweden-based Calliditas' kidney disease drug
The U.S. Food and Drug Administration (FDA) granted full approval to Swedish drugmaker Calliditas Therapeutics' drug to treat rare kidney disease IgA Nephropathy (IgAN), the company said on Wednesday.
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
STOCKHOLM , Dec. 20, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the U.S. Food and Drug Administration (FDA) has appro...
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®
STOCKHOLM , Dec. 11, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that it has received a Notice of Allowance from the United S...